Robert Deziel
Boehringer Ingelheim
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert Deziel.
Bioorganic & Medicinal Chemistry Letters | 1998
Montse Llinas-Brunet; Murray D. Bailey; Robert Deziel; Gulrez Fazal; Vida Gorys; Sylvie Goulet; Ted Halmos; Roger Maurice; Martin Poirier; Marc-André Poupart; Jean Rancourt; Diane Thibeault; Dominik Wernic; Daniel Lamarre
Replacement of the C-terminal carboxylic acid functionality of peptide inhibitors of hepatitis C virus (HCV) NS3 protease (complexed with NS4A peptide cofactor) by activated carbonyl groups does not produce any substantial increase in potency. These latter inhibitors also inhibit a variety of other serine and cysteine proteases whereas the carboxylic acids are specific. Norvaline was identified as a chemically stable replacement for the P1 residue of Ac-DDIVPC-OH which was also compatible with activated carbonyl functionalities.
Bioorganic & Medicinal Chemistry Letters | 2009
Martin Allan; Sukhdev Manku; Eric Therrien; Natalie Nguyen; Sylvia Styhler; Marie-France Robert; Anne-Christine Goulet; Andrea J. Petschner; Gabi Rahil; A. Robert MacLeod; Robert Deziel; Jeffrey M. Besterman; Hannah Nguyen; Amal Wahhab
A series of N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides targeting co-activator associated arginine methyltransferase 1 (CARM1) have been designed and synthesized. The potency of these inhibitors was influenced by the nature of the heteroaryl fragment with the thiophene analogues being superior to thiazole, pyridine, isoindoline and benzofuran based inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2009
David Smil; Sukhdev Manku; Yves Andre Chantigny; Silvana Leit; Amal Wahhab; Theresa P. Yan; Marielle Fournel; Christiane R. Maroun; Zuomei Li; Anne-Marie Lemieux; Alina Nicolescu; Jubrail Rahil; Sylvain Lefebvre; Anthony Panetta; Jeffrey M. Besterman; Robert Deziel
In an effort to identify HDAC isoform selective inhibitors, we designed and synthesized novel, chiral 3,4-dihydroquinoxalin-2(1H)-one and piperazine-2,5-dione aryl hydroxamates showing selectivity (up to 40-fold) for human HDAC6 over other class I/IIa HDACs. The observed selectivity and potency (IC(50) values 10-200 nM against HDAC6) is markedly dependent on the absolute configuration of the chiral moiety, and suggests new possibilities for use of chiral compounds in selective HDAC isoform inhibition.
Bioorganic & Medicinal Chemistry Letters | 2008
Stephen William Claridge; Franck Raeppel; Marie-Claude Granger; Naomy Bernstein; Oscar Mario Saavedra; Lijie Zhan; David Llewellyn; Amal Wahhab; Robert Deziel; Jubrail Rahil; Normand Beaulieu; Hannah Nguyen; Isabelle Dupont; Annie Barsalou; Carole Beaulieu; Ian Chute; Serge Gravel; Marie-France Robert; Sylvain Lefebvre; Marja Dubay; Roussen Pascal; Jeff Gillespie; Zhiyun Jin; James C. Wang; Jeffrey M. Besterman; A. Robert MacLeod; Arkadii Vaisburg
A series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases is described. The compounds demonstrated potency with IC(50) values in the low nanomolar range in vitro while the lead compound also showed in vivo activity against various human tumor xenograft models in mice. Further exploration of this class of compounds is underway.
Tetrahedron Letters | 1997
Robert Deziel; Eric Malenfant; Carl Thibault; Sylvie Frechette; Michel Gravel
Abstract The enantioselective synthesis of a new and extremely effective organoselenium reagent ( 2 ) is reported. This chiral reagent was found to react with alkenes with a very high degree of facial selectivity in selenomethoxylation and ring closure reactions. In some cases the diastereoselectivities were found to be as high as 98%.
Bioorganic & Medicinal Chemistry Letters | 1998
Robert Deziel; Eric Malenfant
Monocyclic β-lactams have been identified as potent and selective inhibitors of the human cytomegalovirus protease (HCMV) No. Two series of these inhibitors are described, a peptidyl series of compounds and non-peptidic molecules featuring lower molecular weights. The SAR work that lead to the discovery of these inhibitors, together with their synthesis is also disclosed.
Bioorganic & Medicinal Chemistry Letters | 2009
Pierre Tessier; David Smil; Amal Wahhab; Silvana Leit; Jubrail Rahil; Zuomei Li; Robert Deziel; Jeffrey M. Besterman
We have identified a series of diphenylmethylene hydroxamic acids as novel and selective HDAC class IIa inhibitors. The original hit, N-hydroxy-2,2-diphenylacetamide (6), has sub-micromolar class IIa HDAC inhibitory activity, while the rigidified oxygen analogue, N-hydroxy-9H-xanthene-9-carboxamide (13), is slightly more selective for HDAC7 with an IC(50) of 0.05muM. Substitution of 6 allows for the modulation of selectivity and potency amongst the class IIa HDAC isotypes.
Bioorganic & Medicinal Chemistry | 1999
William W. Ogilvie; Christiane Yoakim; F. Dô; Bruno Haché; Lisette Lagacé; Julie Naud; Jeff O'Meara; Robert Deziel
A series of monobactam inhibitors of HCMV (N(o)) protease bearing a heterocycle linked by a methylene group at C-4 is described. Inhibitors containing a heterocycle such as a 2-furyl, 2-thiophenyl, 4-methyl-2-tetrazole and 2-benzothiazole were found to be active in a plaque reduction assay. Furthermore, 2-benzothiazole derivatives were shown to inhibit the HCMV protease activity inside cells by using a cell transfection assay, indicating that their antiviral activity in the plaque reduction assay could be attributed to protease inhibition.
Bioorganic & Medicinal Chemistry Letters | 2009
Michael Mannion; Stephane Raeppel; Stephen William Claridge; Nancy Zhou; Oscar Mario Saavedra; Ljubomir Isakovic; Lijie Zhan; Frédéric Gaudette; Franck Raeppel; Robert Deziel; Normand Beaulieu; Hannah Nguyen; Ian Chute; Carole Beaulieu; Isabelle Dupont; Marie-France Robert; Sylvain Lefebvre; Marja Dubay; Jubrail Rahil; James C. Wang; Hélène Ste-Croix; A. Robert MacLeod; Jeffrey M. Besterman; Arkadii Vaisburg
A series of N-(4-(6,7-disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides targeting c-Met and VEGFR2 tyrosine kinases was designed and synthesized. The compounds were potent against these two enzymes with IC(50) values in the low nanomolar range in vitro, possessed favorable pharmacokinetic profiles and showed high efficacy in vivo in several human tumor xenograft models in mice.
Tetrahedron Letters | 1998
Robert Deziel; Eric Malenfant; Carl Thibault
Abstract Asymmetric arene-alkene cyclization reactions mediated by a chiral electrophilic organoselenium reagent afforded substituted carbocyclic derivatives with high diastereoselectivities. It was also found that β-methoxyselenides are good precursors of seleniranium ions when treated with strong acids.